Arcutis Biotherapeutics Inc (ARQT)
$23.90
$0.24
(1.01%)
As on 04-Sep-2026 16:00EDT
Market cap
$3,004 Mln
Revenue (TTM)
$464 Mln
P/E Ratio
108.6
P/B Ratio
13.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
62.8
-
Debt to Equity
0.5
-
Book Value
$1.8
-
EPS
$0.2
-
Face value
--
-
Shares outstanding
125,691,961
7 Years Aggregate
CFO
$-853.13 Mln
EBITDA
$-943.92 Mln
Net Profit
$-991.24 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Arcutis Biotherapeutics Inc (ARQT)
| -17.7 | -7.9 | 11.9 | 49.9 | 38.7 | 2.0 | -- |
|
BSE Sensex*
| -10.1 | -3.6 | 2.5 | -5.7 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Arcutis Biotherapeutics Inc (ARQT)
| 108.5 | 326.2 | -78.2 | -28.6 | -26.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Arcutis Biotherapeutics Inc (ARQT)
|
23.9 | 3,004.0 | 464.0 | 28.5 | 8.9 | 13.9 | 108.6 | 13.5 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and... atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Read more
-
President, CEO & Director
Mr. Todd Franklin Watanabe M.A.
-
President, CEO & Director
Mr. Todd Franklin Watanabe M.A.
-
Headquarters
Westlake Village, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Arcutis Biotherapeutics Inc (ARQT)
What is the current share price of Arcutis Biotherapeutics Inc (ARQT) Today?
The share price of Arcutis Biotherapeutics Inc (ARQT) is $23.90 (NASDAQ) as of 04-Sep-2026 16:00 EDT. Arcutis Biotherapeutics Inc (ARQT) has given a return of 38.69% in the last 3 years.
What is the current PB & PE ratio of Arcutis Biotherapeutics Inc (ARQT)?
The P/E ratio of Arcutis Biotherapeutics Inc (ARQT) is 108.64 times as on 04-Sep-2026.
The P/B ratio of Arcutis Biotherapeutics Inc (ARQT) is 13.48 times as on 04-Sep-2026, a 153 premium to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-244.03 |
20.79 |
2024 |
-12.03 |
10.70 |
2023 |
-1.14 |
3.37 |
2022 |
-2.90 |
4.30 |
2021 |
-5.06 |
3.50 |
What is the 52 Week High and Low of Arcutis Biotherapeutics Inc (ARQT)?
The 52-week high and low of Arcutis Biotherapeutics Inc (ARQT) are Rs 31.77 and Rs 16.21 as of 07-Sep-2026.
What is the market cap of Arcutis Biotherapeutics Inc (ARQT)?
Arcutis Biotherapeutics Inc (ARQT) has a market capitalisation of $ 3,004 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Arcutis Biotherapeutics Inc (ARQT)?
Before investing in Arcutis Biotherapeutics Inc (ARQT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.